Related Experiment Videos

Pharmacokinetics of phenobarbitone in protein energy malnutrition

Developmental Pharmacology and Therapeutics
|January 1, 1986
PubMed

Insights

Malnourished children exhibit significantly prolonged phenobarbitone elimination half-life and higher bioavailability compared to healthy children. Dosage adjustments are recommended for phenobarbitone in pediatric malnutrition.

Area of Science:

  • Pharmacokinetics
  • Pediatric Medicine
  • Nutritional Science

Background:

  • Phenobarbitone is a widely used anticonvulsant in pediatric populations.
  • Nutritional status can significantly impact drug metabolism and elimination.
  • Understanding drug kinetics in malnourished children is crucial for safe and effective treatment.

Purpose of the Study:

  • To investigate and compare the pharmacokinetics of phenobarbitone in malnourished versus healthy children.
  • To determine the impact of protein-energy malnutrition on phenobarbitone absorption, distribution, metabolism, and excretion.

Main Methods:

  • A single oral dose of phenobarbitone (approximately 7.0 mg/kg) was administered to both malnourished and healthy children.
  • Serum phenobarbitone concentrations were measured using a spectrophotometric method.
  • Key pharmacokinetic parameters including elimination half-life (t1/2) and time to maximum concentration (tmax) were analyzed.

Main Results:

  • The elimination half-life of phenobarbitone was significantly longer in malnourished children (58.9 ± 9.5 h) compared to healthy children (30.15 ± 6.1 h).
  • Time to maximum concentration (tmax) was prolonged in the malnutrition group, indicating slower drug absorption.
  • Systemic bioavailability of phenobarbitone was found to be higher in children with protein-energy malnutrition.

Conclusions:

  • Protein-energy malnutrition substantially alters phenobarbitone pharmacokinetics in children.
  • Altered absorption and prolonged elimination necessitate modifications to standard phenobarbitone dosage regimens in malnourished pediatric patients.
  • Further research into optimized dosing strategies for phenobarbitone in pediatric malnutrition is warranted.

Related Concept Videos